Menu
← Oncology Approval Tracker
FDA DECISION ·
Calquence + Venclexta
acalabrutinib with venetoclax · AstraZeneca / AbbVie / Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, using either approved acalabrutinib tablets or capsules with venetoclax.
LAMPGEN ANALYSIS
Why it matters
This provides a fixed-duration BTK and BCL-2 inhibitor combination. AMPLIFY studied previously untreated patients without del(17p) or TP53 mutation, which is relevant when applying the trial evidence.
What research teams should watch
Plan for venetoclax ramp-up, tumor lysis risk assessment and lab timing. Report the molecular exclusions separately from the approved use.
PRIMARY RECORDS